Dan O'Day, Gilead CEO (Andrew Harnik/AP Images)
Gilead wins approval for long-acting HIV injection after resolving vial concerns
Gilead finally gained FDA approval on Thursday for lenacapavir, its closely-watched capsid inhibitor for HIV-1, the most common type of HIV.
Lenacapavir will be marketed in the US as Sunlenca for heavily pretreated HIV-1 patients who are failing their current antiretroviral regimen. The long-acting subcutaneous injection is administered just twice a year, offering an alternative to cumbersome daily pill regimens.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters